“…A total of 4,852 patients were enrolled (sample size: maximum: 702, minimum: 47, and mean: 167), and 16 carcinoma types were analyzed, including lung cancer (6, different subtypes), colorectal cancer (4), bladder cancer (2), breast cancer (2), gallbladder cancer (2), gastric cancer (2), ovarian carcinoma (2), cervical cancer (1), endometrioid endometrial carcinoma (1), extranodal natural killer (NK)/T cell lymphoma/nasal type (1), hilar cholangiocarcinoma (1), laryngeal squamous cell carcinoma (1), nasopharyngeal carcinoma (1), pancreatic cancer (1), pituitary adenomas (1), and squamous cell carcinoma of oral cavity (1). A total of 47 HRs/RRs were extracted from 29 studies, including 26 for OS, 6 for DFS, 15 , 34 , 35 , 41 , 44 , 56 5 for PFS, 13 , 34 , 35 , 39 , 57 4 for DR, 38 , 49 , 57 , 58 3 for CSS, 55 and 1 for DFS/PFS. 59 Study quality was evaluated by using the Newcastle–Ottawa Scale (NOS), and the quality scores ranged from 6 to 9, suggesting high methodological quality.…”